贝达药业股份有限公司 关于修订、制定公司部分治理制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300558 证券简称：贝达药业 公告编号：2026-005 上述制度的修订、制定已经公司第五届董事会第一次会议审议通过，制度全 文详见公司同日披露在巨潮资讯网（www.cninfo.com.cn）上的相关内容。 特此公告。 为进一步提升规范运作水平，完善治理结构，根据《中华人民共和国公司法》 《上市公司章程指引》《深圳证券交易所创业板股票上市规则》《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律法规、规范性文件的规定，贝达药业股份有限公司（以下 简称"公司"）于 2026 年 1 月 30 日召开的第五届董事会第一次会议，审议通过 了《关于修订、制定公司部分治理制度的议案》，对部分管理制度进行修订、制 定，具体如下： | 序号 | 制度名称 | 类型 | 是否提交 股东会审议 | | --- | --- | --- | --- | | 1 | 《独立董事专门会议工作制度（2026 ...

证券代码：300558 证券简称：贝达药业 公告编号：2026-004 贝达药业股份有限公司 关于董事会完成换届选举 及聘任高级管理人员和其他相关人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"贝达药业"或"公司"）第四届董事会 及高级管理人员任期已经届满，公司于 2025 年 12 月 31 日召开了 2025 年第二次 临时股东大会，于 2026 年 1 月 30 日召开了第五届董事会第一次会议，完成了董 事会的换届选举和新一届高级管理人员、证券事务代表的聘任。现将具体情况公 告如下： 一、第五届董事会组成情况 非独立董事：丁列明先生（董事长）、TI A N X U（许田）先生、 YONGJUN LIU（刘勇军）先生、万江先生、LI MAO（毛力）先生、范建勋先 生、童佳女士 职工董事：丁师哲先生 独立董事：黄欣琪女士、肖佳佳女士、JIANWEI XUAN（宣建伟）先生、 叶建亮先生 公司第五届董事会由 12 名成员组成，任期三年，自本次董事会审议通过之 日起至第五届董事会任期届满为止。上述董事会成员中兼任公司高 ...

修订对照表 | 原条款 | | 修订后的条款 | | --- | --- | --- | | 第三章 | 股份 | 第三章 股份 | | 第十六条 | 公司的股份采取股票的形式。 | 第十六条 公司的股份采取记名股票的形式。 | | | | 如公司的股本包括无投票权的股份，则该等股份的名称须加上"无 | | | | 投票权"的字样。如股本资本包括附有不同投票权的股份，则每一 | | | | 类别股份（附有最优惠投票权的股份除外）的名称，均须加上"受 | | | | 限制投票权"或"受局限投票权"的字样。 | | 第四章 | 股东和股东会 | 第四章 股东和股东会 | | 第六十二条 股权登记日登记在册的所有股东或其代理人，均有权 | | 第六十二条 股权登记日登记在册的所有股东或其代理人，均有权 出席股东会。并依照有关法律、法规及本章程行使表决权（除非个 | | 出席股东会。并依照有关法律、法规及本章程行使表决权（除非个 | | | | 别股东受公司股票上市地证券监管规则规定须就个别事宜放弃投 | | 别股东受公司股票上市地证券监管规则规定须就个别事宜放弃投 | | | | 票权）。 | | 票权）。 | | ...

证券代码：300558 证券简称：贝达药业 公告编号：2026-003 贝达药业股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会会议通知于 2026 年 1 月 23 日以电话、邮件等形式送达全体 董事，董事会会议通知中包括会议的相关材料，同时列明了会议的召开时间、地 点、内容和方式。 2、本次董事会于 2026 年 1 月 30 日在公司杭州总部行政大楼会议室召开， 采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 12 人，实际出席会议人数 12 人。 4、本次董事会由全体董事推举丁列明先生主持，公司董事会秘书吴灵犀先 生列席了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《贝达药业股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《关于选举公司第五届董事会董事长暨代表公司执行公司事务 董事的议案》 公司 2025 ...

Core Viewpoint - The company, Betta Pharmaceuticals, is advancing two innovative drug candidates aimed at treating specific types of cancer, with a commitment to timely information disclosure regarding significant developments [1]. Group 1: Drug Development - The self-developed BPI-520105 tablets are a new, highly selective pan-EGFR small molecule inhibitor targeting patients with solid tumors carrying epidermal growth factor receptor (EGFR) mutations [1]. - The BPI-572270 capsules are a novel, potent pan-RAS "non-degradable molecular glue" inhibitor intended for the treatment of patients with advanced malignant solid tumors [1]. - Both projects are progressing in accordance with clinical research plans [1].

Core Viewpoint - The company emphasizes its commitment to strategic partnerships and global business expansion, actively seeking diverse collaboration opportunities with leading global biopharmaceutical firms [1] Group 1 - The company is focused on aligning its research and development strategy with its pipeline layout [1] - The company is engaging with top global biopharmaceutical enterprises to explore various collaboration methods [1] - The company will promptly announce any significant progress in strategic partnership projects [1]

Group 1 - The company has scheduled April 23, 2026, as the disclosure date for its 2025 annual report [1] - The company confirmed that its operations are currently normal [1] - Investors are advised to refer to the company's public disclosures for information related to the 2025 performance [1]

Summary of Key Points Core Viewpoint - On January 28, 2026, BeiGene conducted a block trade involving 106,100 shares at a transaction price of 38.33 yuan, which represents a discount of 20.85% compared to the market closing price of 48.43 yuan [1]. Group 1: Transaction Details - The total transaction amount for the block trade was 4.0668 million yuan, accounting for 0.97% of the total trading volume on that day [1]. - The buyer and seller of the shares were both from CITIC Securities Co., Ltd., specifically the Beijing Chaoyang branch [2].

Core Insights - In 2025, Hangzhou is set to have five Class 1 new drugs approved, accounting for 83% of the total in the province, marking a historical high and showcasing the city's strength in biopharmaceutical innovation [1] - The establishment of the Hangzhou Biopharmaceutical and Medical Device Industry Alliance aims to enhance resource circulation and address challenges such as fragmented innovation resources and insufficient collaboration within the industry [1][2] Group 1 - The alliance comprises 249 member units from various sectors, including government, industry, academia, research, healthcare, and finance, creating a comprehensive innovation community [2] - The alliance will implement three main mechanisms: quarterly activities, resource sharing, and demand response to empower member units effectively [2] - The first rotating chairman of the alliance, Ding Lieming from Betta Pharmaceuticals, emphasized the importance of the alliance in building a platform for resource sharing and collaborative innovation among biopharmaceutical companies [2] Group 2 - The alliance will focus on cutting-edge fields such as synthetic biology, nucleic acid drugs, and AI in pharmaceuticals, promoting deep integration of innovation chains, industry chains, capital chains, and talent chains [3] - The alliance will also serve as a high-end think tank, leveraging the expertise of its members to provide scientific support for the planning and decision-making of the biopharmaceutical industry cluster in Hangzhou [2]

Group 1 - The core theme of the conference was "innovation-driven," highlighted by the success story of the first small molecule targeted anti-cancer drug, Camrelizumab, developed by Betta Pharmaceuticals, which took nearly a decade from initiation in 2002 to market launch in 2011 [1] - The biopharmaceutical industry is experiencing unprecedented innovation opportunities due to the continuous change in disease patterns, which current treatment methods cannot fully address [2] - The integration of big data and artificial intelligence (AI) is revolutionizing new drug development, reducing the average research and development cycle and costs by approximately 50% [2] Group 2 - In the past year, China approved 76 innovative drugs and medical devices, with a total transaction value of over $130 billion for innovative drug licensing, marking a historical high and establishing China as a global source of pharmaceutical innovation [3] - The biopharmaceutical industry in Hangzhou is characterized by a collaborative ecosystem, with various stakeholders providing support to overcome challenges in drug development, particularly in preclinical research and clinical translation [4] - The Hangzhou Capital Group is actively supporting enterprises with core technologies and development potential, providing stable financial resources to facilitate innovation throughout the entire lifecycle of companies [4] Group 3 - Local institutions, including the Hangzhou Biobank and Tigermed, are committed to enhancing collaboration in resource sharing, professional services, and research platform construction to strengthen the innovation foundation of Hangzhou's biopharmaceutical industry [5]